Edition:
United Kingdom

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

5.85USD
15 Aug 2018
Change (% chg)

$-0.11 (-1.85%)
Prev Close
$5.96
Open
$5.88
Day's High
$5.88
Day's Low
$5.81
Volume
7,798
Avg. Vol
69,056
52-wk High
$13.05
52-wk Low
$4.78

Chart for

About

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product... (more)

Overall

Beta: -0.54
Market Cap(Mil.): $171.73
Shares Outstanding(Mil.): 19.06
Dividend: --
Yield (%): --

Financials

  REPH.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -2.17 -- --
ROI: -23.45 1.78 14.61
ROE: -74.12 3.28 16.33

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

24 May 2018

UPDATE 2-Recro Pharma shares plummet after FDA rejects non-opioid pain shot

* FDA says drug's pain-relieving effect did not meet expectations

24 May 2018

BRIEF-Recro Pharma Receives Complete Response Letter From FDA

* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA

24 May 2018

FDA declines to approve Recro Pharma's non-opioid pain shot

The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.

24 May 2018

BRIEF-Recro Pharma Reports Q1 Loss Per Share Of $0.65

* Q1 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S

09 May 2018

BRIEF-Recro Pharma Announces Receipt Of Issue Notifications For Three New Patents For Iv Meloxicam

* RECRO PHARMA ANNOUNCES RECEIPT OF ISSUE NOTIFICATIONS FOR THREE NEW PATENTS FOR IV MELOXICAM Source text for Eikon: Further company coverage:

07 May 2018

BRIEF-Recro Pharma Inc Reports Year End 2017 Financial Results

* RECRO PHARMA INC - FOR 2018, COMPANY EXPECTS REVENUE GENERATED FROM ITS CDMO DIVISION TO BE APPROXIMATELY $70 MILLION

27 Feb 2018

Earnings vs. Estimates